More than half of Americans face financial difficulties paying for medical treatment, according to a recent study. This is particularly relevant in rare diseases and cancer and exacerbates health issues while causing mounting anxiety. Read More

Early diagnosis and treatment of homozygous familial hypercholesterolemia (HoFH) are key to reducing patients' risk, yet there is low awareness of current guidelines and treatment options among healthcare practitioners. Read More

Targeted therapies have allowed for better management of neuroendocrine tumors (NETs), yet this requires that healthcare providers glean new knowledge about treatment options such as somatostatin analogs. To improve provider competency and include consideration of patient perspectives in treatment selection, PlatformQ Health and Healing NET Foundation teamed up with the Moffitt Cancer Center to produce a free educational initiative for providers. Read More

In the face of a rapidly shifting landscape of targeted therapies for treating gMG, PlatformQ Health, the National Organization for Rare Disorders (NORD), and the University of North Carolina at Chapel Hill collaborated to develop online CME education about the management of this disease.  Read More

Patients often face an epic journey of many years before receiving a diagnosis for a rare disease. With nearly one in 10 Americans impacted by a rare condition, it is essential that we decrease the time to diagnosis to improve the lives of these individuals and their families.  Read More

The management of developmental and epileptic encephalopathies (DEEs) has shifted in recent years, necessitating changes in treatment decisions. In the wake of these changes, PlatformQ Health, the National Organization for Rare Disorders, the Lennox Gastaut Syndrome Foundation, and the University of California, San Francisco came together to produce aligned, online continuing education to support healthcare providers in their ability to diagnose and treat DEEs and help caregivers to engage in care. Read More

Ongoing clinician and public education on rare diseases is critical to raising the index of suspicion, decreasing the time to diagnosis, and providing optimal management of patients with these conditions.  Read More

In our latest partnership newsletter, we highlight some of our recent educational initiatives that address clinical trial equity, tethered education, strategies to improve CME outcomes and more! Read More

High-quality education takes shape when the needs of patients and providers are anticipated and met through an ever-evolving education model. Read More

PlatformQ Health presents a poster at the 2022 ASCO Quality Care Symposium on educational outcomes in Urothelial Carcinoma. Read More

Educational outcomes from “Evolving Treatment Approaches for Generalized Myasthenia Gravis to Reduce Disease Burden and Improve Daily Living" accepted at the MGFA Scientific Session at the 2022 AANEM Conference. Read More

People of color, the elderly, as well as those living in rural areas are disproportionately affected by cancer, yet are severely underrepresented in cancer clinical trials. The lack of diversity in clinical trials leaves these patients at a severe disadvantage because there is little insight into the safety and effectiveness of therapies for them. Read More